Clinical Trials Logo
  1. Home
  2. Retinitis Pigmentosa
  3. NCT04805658
  4. Details
NCT04805658 Clinical Trial

Natural History Study of Retinitis Pigmentosa Type 11

Retinitis Pigmentosa Clinical Trial

— ReSa  

Official title:
Natural History Study of Retinitis Pigmentosa Type 11

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT04805658
Other study ID # 179417
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date February 1, 2021
Est. completion date February 1, 2025

Study information
Verified date March 2023
Source Oslo University Hospital
Contact Josephine P Holtan, MD
Phone +22118589
Email jospre@ous-hf.no
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Observational study of patients with retinitis pigmentosa type 11

Description:

Natural history study with clinical examination every 6 months.

Recruitment information / eligibility
Status Recruiting
Enrollment 40
Est. completion date February 1, 2025
Est. primary completion date July 1, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Clinical diagnosis of retinitis pigmentosa caused by a disease-causing mutation involving the PRPF31 gene - Or disease-causing mutation involving the PRPF31 gene without the clinical diagnosis of retinitis pigmentosa Exclusion Criteria: - Under 18 years - Other types of retinitis pigmentosa

Study Design

Related Conditions & MeSH terms

Intervention

Diagnostic Test:
• Clinical examinations
Clinical examinations

Locations
Country Name City State
Norway Department of Ophthalmology, Oslo University Hospital Oslo

Sponsors (1)
Lead Sponsor Collaborator
Oslo University Hospital

Country where clinical trial is conducted

Norway, 

Outcome
Type Measure Description Time frame Safety issue
Primary Progression of disease Retinal function measured by functional and structural testing 24 mounths
See also
  Status Clinical Trial Phase
Recruiting NCT01432847 - Cell Collection to Study Eye Diseases
Completed NCT04983914 - Retrospective NIS to Evaluate the Patient Benefit of TES
Recruiting NCT03845218 - Retinitis Pigmentosa Clinical Measures and Repeatability Testing of Potential Outcome Measures
Completed NCT00231010 - Molecular Genetics of Retinal Degenerations
Active, not recruiting NCT04611503 - PDE6A Gene Therapy for Retinitis Pigmentosa Phase 1/Phase 2
Completed NCT02909985 - Visual Activity Evoked by Infrared in Humans After Dark Adaptation N/A
Recruiting NCT01914913 - Clinical Study to Evaluate Safety and Efficacy of BMMNC in Retinitis Pigmentosa Phase 1/Phase 2
Completed NCT01949623 - Biomarkers In Retinitis Pigmentosa (BIRP) N/A
Completed NCT01835002 - Transcorneal Electrical Stimulation - Multicenter Safety Study N/A
Completed NCT00407602 - Argus® II Retinal Stimulation System Feasibility Protocol N/A
Completed NCT00515814 - Retina Implant Pilot Trial to Evaluate Safety & Efficacy in Blind Patients Having Degenerated Photo-receptors N/A
Completed NCT00100230 - DHA and X-Linked Retinitis Pigmentosa Phase 2
Active, not recruiting NCT00378742 - Repository for Inherited Eye Diseases
Terminated NCT05085964 - An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa Phase 2
Recruiting NCT05805007 - Safety and Tolerability Study of Gene Editing Drug ZVS203e in Participants With Retinitis Pigmentosa Early Phase 1
Recruiting NCT05909488 - Role of UC-MSC and CM to Inhibit Vision Loss in Retinitis Pigmentosa Phase I/II Phase 2/Phase 3
Recruiting NCT06291935 - Safety and Tolerability of Intravitreal Administration of VG901 in Patients With Retinitis Pigmentosa Due to Mutations in the CNGA1 Gene Phase 1
Recruiting NCT03078309 - The Effects of Cannabis on Visual Functions in Healthy and Retinitis Pigmentosa Patients Early Phase 1
Completed NCT04238858 - Effects of Subtenon-injected Autologous Platelet-rich Plasma on Visual Functions in Eyes With Retinitis Pigmentosa N/A
Active, not recruiting NCT01680510 - The Effect of Oral Administration of 9-cis β Carotene Rich Powder of the Alga Dunaliella Bardawil Phase 1/Phase 2